Statement on “Medicinal Cannabis” with particular reference to its use in the management of patients with chronic non-cancer pain

1. The Faculty of Pain Medicine (FPM) acknowledges the changed regulatory environment for the use of medicinal cannabis in Australia and New Zealand. In Australia this includes the rescheduling of tetrahydrocannabinol (THC) from S9 (Prohibited substances) to S8 (Controlled drugs) and the granting of licences for the cultivation of Cannabis sativa and the manufacture and production of medicinal cannabinoids. In New Zealand this includes proposed changes to the Misuse of Drugs Act 1975 to allow terminally ill people to possess and use illicit cannabis, to enable regulations to be made setting quality standards for products, and to deschedule cannabidiol (CBD) as a controlled drug. THC would remain a class B controlled drug, except when contained in a class C controlled drug, and except when contained in a CBD product.

2. FPM recognises both the political imperatives underpinning these changes and the community demands that have generated them.

3. FPM adheres to the principle that substances intended for therapeutic purposes be fully characterised chemically, pharmacologically and toxicologically, to the extent that they would be eligible for registration by regulatory authorities (Therapeutic Goods Administration in Australia; Medsafe in New Zealand).

4. The sociopsychobiomedical framework that informs the assessment and management of people with chronic non-cancer pain requires active engagement of patients in a multimodal management program, and recognises the adverse effects that may be associated with polypharmacy in general and with cannabinoids in particular.

5. FPM is very concerned about the adverse event profile in cannabis users, especially in young people, including impaired respiratory function, psychotic symptoms and disorders and cognitive impairment.

6. At the present time, the scientific evidence for the efficacy of cannabinoids in the management of people with chronic non-cancer pain is insufficient to justify endorsement of their clinical use.

7. FPM recognises the difficulties inherent in performing trials of any medications in patients with chronic non-cancer pain. Nonetheless FPM believes that if pragmatic trials of cannabinoids are considered to be necessary they should be conducted on a coordinated national basis.

BACKGROUND NOTES

THE LANDSCAPE

- Worldwide, cannabis is the third most commonly used substance after alcohol and tobacco.
- Unauthorised use of cannabis as a medicine in Australia is widespread (Swift et al, 2005).
- 92% of respondents to the 2012 Illicit Drug Reporting System survey in Australia reported that hydroponic cannabis was “easy” or “very easy” to obtain (Stafford & Burns, 2012)
- In the general population, 4.7% of those aged over 40 years had used cannabis in the past year (Australian Institute of Health and Welfare, 2011)
In populations of pain patients:

• Prevalence of use in chronic pain clinics: 12-15% (Ware et al, 2002, 2003)\(^1\)
• Chronic pain is the most common “reason” for patients to report “medical” use of cannabis in the United States (USA) (Dyer 2013) (inverted commas added).

**Complexity of chronic pain phenotype**

Baseline data from the POINT study\(^2\) being conducted by the National Drug and Alcohol Research Centre at UNSW Sydney have illustrated in more detail the complexity of the phenotype of chronic non-cancer pain (Campbell et al, 2015; Degenhardt et al, 2015).

Findings include:

• Complex clinical profiles were more prevalent among the younger age-groups (‘working’ and ‘nearing retirement’ age groups). These groups reported more mental health problems, more experience of childhood abuse/neglect and lifetime suicidality, and more substance use than the retirement age-group.

• These two groups were also prescribed higher doses of opioids, were more likely to be prescribed codeine as well, and were likely to be taking concurrently prescribed benzodiazepines, antidepressants and antipsychotics.

• Just under half met criteria for current moderate/severe depression, with a substantial minority meeting criteria for:
  - current moderate/severe anxiety or agoraphobia
  - lifetime suicidal ideation
  - lifetime alcohol use disorder

• Almost half (43±2% 95% CI) of the sample had used cannabis for recreational purposes at some time.

• One in eight (12±2%) of the entire cohort met ICD-10 criteria for lifetime cannabis use disorder

• One in six of the cohort (15±2%) had used cannabis for pain relief.

• A quarter (24±2%) reported that they would use cannabis for pain relief if they had access to it.

**THE SUBSTANCES\(^3\)**

**Cannabis** (from Latin, meaning hemp)

• Various preparations derived from the plant Cannabis sativa

• Synonyms: marijuana (USA), dope, draw, ganja, grass, pot, puff, smoke, toke, weed. Street names for varieties of cultivated cannabis are: Northern Lights, Haze, Purple Haze, White Widow, Skunk#1, Sensie Star, Orange Bud, Bubblegum, Hindu Kush, Chronic, and Jack Herer.

• Herbal cannabis: leaves and compressed female flower heads of Cannabis sativa; also known as weed, grass, ganja, herb, green, thai stick, and bud or bush.

• Resin: compressed tetrahydrocannabinol (THC)-rich bracts from Cannabis plants; also known as hashish, hash, black, blonde polm, rocky, dark rocky, slate, and soapy or soap bar.

• Concentrations of chemical constituents can vary by plant strain and by conditions of growing, storage, harvest and preparation.

• Pharmacological effects may be enhanced by synergies between constituents of cannabis not present in isolated or synthetic cannabinoid pharmaceuticals.

• Standardisation of any plant material, extract or blend for medicinal use is essential, and the chemovar (or chemotype) is the most reliable predictor of medicinal value.

---

\(^1\) Note: USA data; some from more than a decade ago

\(^2\) A prospective study in Australia of 1500 patients who have been prescribed opioids for CNCP.

\(^3\) From Mather 2005, Mather et al 2013, RCP 2005, APM4e
Cannabinoids

- Substances (regardless of chemical structure or whether they are natural or synthetic) that bind to biological receptors and produce the classical spectrum of pharmacological effects demonstrated by extracts of *C. sativa*.
- Principal botanical cannabinoids are
  - delta9-tetrahydrocannabinol (THC)
  - cannabidiol (CBD)
  - cannabinol⁴ (CBN)

Preparations currently available

A. Medical extracts from *Cannabis sativata*:

- nabiximols (Sativex®)
  - oromucosal spray
  - 2.7mg THC and 2.5mg CBD per 100µl
  - max 16 sprays per day
  - indications:
    - adjunctive treatment for the symptomatic relief of neuropathic pain in patients with multiple sclerosis (Canada)
    - adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain (Canada)
    - spasticity in multiple sclerosis (Australia, UK, EU)

- whole plant extract (Cannador)
  - THC 2.5g and CBD 1.2mg
  - Oral capsule

- standardised plant matter in granular form (produced by Bedrocan BV for the Netherlands Ministry of Health, Welfare and Sport; pharmacy-supplied for vaporisation or tea preparation)
  - THC:CBD 19:1 (Bedrocan),
  - 12:<1 (Bedrobinol),
  - 6:75 (Bediol),
  - 14:< 1 (Bedica)

B. Synthetic cannabinoids:

- dronabinol (Marinol®)
  - synthetic THC
  - oral capsule, 2.5mg, 5mg, 10mg
  - max dose 20mg per day
  - Indications:
    - stimulation of appetite in AIDS-related anorexia and weight loss
    - severe nausea and vomiting associated with cancer chemotherapy

- nabilone (Cesamet®)
  - synthetic THC analogue
  - oral capsule, 0.25mg, 0.5mg, 1mg
  - max dose 6mg per day
  - indications:
    - severe nausea and vomiting associated with cancer chemotherapy

⁴ CBD and CBN have not been adequately evaluated in treatment of pain
Pharmacology
Some pharmacokinetic considerations:
Transpulmonary (inhaled)
• rapid absorption
• rapid onset of effect
• bioavailability ~18%
• inaccurate dosing
• levels fall within 2h
Oral (and transmucosal)
• poor absorption
• low bioavailability (<10%)
• difficult to titrate

Mather 2005: “Any successful future clinical development of cannabinoid pharmacotherapy depends upon a dosage form that is reliable, rapidly titratable to effect, non-smoked, non-injected, and preferably parenteral to avoid hepatic first pass metabolism.”

TGA GUIDANCE

This authoritative document arose out of a systematic review, commissioned by the Department of Health, by a team from the University of New South Wales, University of Sydney and University of Queensland under the coordination of the National Drug and Alcohol Centre (NDARC), which was tasked to assess the available evidence for the use of medicinal cannabis in chronic non-cancer pain (Stockings et al, 2018) and four other settings (palliative care, epilepsy, chemotherapy-induced nausea and vomiting, and multiple sclerosis.

The Recommendations in the TGA guidance document are as follows:
• A comprehensive sociopsychobiomedical assessment of the patient with CNCP is appropriate.
• The use of medications, including medicinal cannabis, is not the core component of therapy for CNCP;
• Patient education is a critical component of therapy for CNCP, particularly with respect to expectations of drug therapy.
• There is a need for larger trials of sufficient quality, size and duration to examine the safety and efficacy of medicinal cannabis use in CNCP. (p. 3)
• In the absence of strong evidence for dosing and specific preparations of cannabis or cannabinoids in the treatment of CNCP, it is recommended that any treating physician who elects to initiate cannabinoid therapy should assess response to treatment, effectiveness and adverse effects after 1 month. This is best achieved as part of a research project or clinical audit. (p.14)

FPM endorses these recommendations.
THE EVIDENCE


This rigorous, comprehensive review identified 104 studies (n = 9958 participants), comprising 47 randomised controlled trials (24 parallel, 23 cross-over) and 57 observational studies. Diagnostic groups included “neuropathic5 pain” (48 studies), “fibromyalgia” (7), MS6-related pain (13), and “mixed or undefined CNCP” (29).

The most commonly studied outcomes were pain intensity (100 studies), adverse events (81) and withdrawals (71). Fewer studies reported on physical functioning (52), emotional functioning (43), and patient’s global impression of change (24). Only two studies in which pain was the primary indication reported on all six outcomes.

Pain was the primary indication in 76 studies and a secondary indication in 28 studies. Of the 104 included studies, four (n = 47 participants) examined cannabinoids as a first-line therapy, and 87 examined cannabinoids as a second-line therapy in addition to existing medication regimens. In nearly all RCT studies, patients were required to be on a stable dose of current medication before commencement of the trial. The most commonly studied cannabinoid was nabiximols, followed by Cannabis sativa.

The main findings regarding pain included:

• Across all CNCP conditions, cannabinoids were more likely than placebo to produce a 30% reduction in pain (OR 1.46, 95%CI 1.16-1.84). The NNTB7 was 24 (95% CI 15 to 61).
• There was no significant evidence that cannabinoids reduced pain by 50% compared to placebo (OR 1.43, 95% CI 0.97-2.11)
• Cannabinoids overall were associated with a larger reduction in pain intensity than placebo (SMD -0.14, 95%CI -0.20 to -0.08). This was calculated to be a reduction of about 3mm (95%CI -5 to -1) on a 0-100mm VAS.

CNCP patients who received a cannabinoid had twice the odds of withdrawing from a trial for any reason than patients who received placebo, and 3.5 times the odds of withdrawing because of adverse events. Similarly CNCP patients who received a cannabinoid had 2.3 times the odds of experiencing an adverse event compared to placebo. The NNTH8 for any adverse event was 6 (95%CI 5 to 8).

There were no significant impacts upon physical or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change.

The authors concluded: “It appears unlikely that cannabinoids are highly effective medicines for CNCP.”

Preceding literature

In the literature that preceded the publication of the TGA Guidance document, there are several reviews on which opinion and advocacy have been based. These are summarised here for completeness.

2017


This document concluded, “There is substantial evidence that cannabis is an effective treatment for chronic pain in adults.” [CONCLUSION 4-1 (page 4-2)] This was based largely on Whiting et al (2015), as the authors commented:

---

5 No distinction made between the pre- and post-2011 definitions of “neuropathic pain”
6 MS: multiple sclerosis
7 NNTB: number needed to treat to benefit
8 NNTH: number needed to treat to harm
“The rigorous screening approach used by Whiting et al. (2015) led to the identification of 28 randomized trials in patients with chronic pain (2,454 participants). Twenty-two of these trials evaluated plant-derived cannabinoids (nabiximols, 13 trials; plant flower that was smoked or vaporized, 5 trials; THC oramucosal spray, 3 trials; and oral THC, 1 trial) while five trials evaluated synthetic THC (i.e., nabilone). All but one of the selected primary trials used a placebo control, while the remaining trial used an active comparator (amitriptyline). The medical condition underlying the chronic pain was most often related to a neuropathy (17 trials); other conditions included cancer pain, multiple sclerosis, rheumatoid arthritis, musculoskeletal issues, and chemotherapy-induced pain. Analyses across seven trials that evaluated nabiximols and one that evaluated the effects of inhaled cannabis suggested that plant-derived cannabinoids increase the odds for improvement of pain by approximately 40 percent versus the control condition (odds ratio [OR] 1.41, 95% confidence interval [CI] = 0.99–2.00; 8 trials). The effects did not differ significantly across pain conditions, although it was not clear that there was adequate statistical power to test for such differences.” (P. 4-3)


This review identified 30 RCTs and 3 cohort studies. Of the 13 trials on “neuropathic pain”, only 4 post-dated the 2011 change in definition, of which 3 used vapourised or smoked THC. In these 4 trials, NNTBs varied from 8.7 (for nabiximols in peripheral neuropathy) to 2.3 (for 6.7% THC in spinal cord injury). Ten trials were only or predominantly in patients with MS: there was “insufficient evidence to characterize the effects of cannabis on pain in patients with MS because of the small number of methodologically rigorous studies, inconsistent findings across studies, lack of long-term outcomes, and small number of patients included in the trials”.

The authors concluded: “Limited evidence suggests that cannabis may alleviate neuropathic pain in some patients, but insufficient evidence exists for other types of chronic pain. Among general populations, limited evidence suggests that cannabis is associated with an increased risk for adverse mental health effects”.

2016


This is a non-critical narrative review of the literature, grouped by agent: nabilone, dronabinol, nabiximols and smoked cannabis. The authors “…amalgamated the studies of chronic pain and neuropathic pain as there appears to be no difference in efficacy between these two modalities” (p. 22).

The authors concluded (p. 33):

“This is a difficult literature to summarise as a number of different formulations have been used and a number of different types of pain have been studied. The authors are also aware of the considerable literature in terms of anecdotal reports, case studies, questionnaires and uncontrolled trials that have also showed efficacy in various types of pain with various formulations.

However, nabilone, dronabinol, nabiximols and smoked marijuana have all been shown to be efficacious to varying extents in a variety of pain settings in good quality studies. We conclude that there is good evidence for efficacy of cannabis for pain relief in various formulations and in a number of settings.” (Emphasis in original)
2015


Until recently this review was the main source of reference. The authors identified 28 studies in chronic pain, involving 2,454 patients in heterogeneous groups, ranging from “neuropathic” pain (12 studies), cancer pain (3 studies), diabetic peripheral neuropathy (3 studies), fibromyalgia (2 studies) and HIV-associated peripheral neuropathy (2 studies). Seventeen studies were considered to be at high risk of bias; 2 were at low risk and 9 were of uncertain risk. Thirteen studies were of nabiximols, 4 studies were of smoked THC, 3 for THC oromucosal spray, 5 of nabilone, 2 of dronabinol; all but one were placebo-controlled.

Overall, “The average number of patients who reported a reduction in pain of at least 30% was greater with cannabinoids than with placebo (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials”. In 6 trials of nabiximols, the weighted mean difference in pain on a 0-10 NRS was −0.46 [95% CI, −0.80 to −0.11] (in favour of the cannabinoid).

The authors concluded: “There was moderate quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity... Cannabinoids were associated with an increased risk of short-term AEs”.


This review identified 24 studies of “chronic neuropathic pain” but 11 were excluded for various quality reasons. Five of the 13 included studies (published between 2003 and 2013) were of nabiximols, 5 of smoked or vaporised cannabis, 1 of dronabinol, 1 of nabilone, with a total of 771 subjects.

The authors found:

“The quasi-totality of the high-quality studies included in the present systematic review suggests that cannabinoids provide significant pain reduction in both the short term and longer term, without significant side effects...” and noted that “Nine out of 13 studies clearly stated a NNT ranging from 2 to 4, with no differences among type of cannabinoids”. Furthermore, “… the present systematic review found very few risks related to the use of cannabinoid compounds in the treatment of chronic neuropathic pain. The vast majority of adverse events listed were considered minor in nature”.


This review examined 6 RCTs (n=226 patients) of nonsynthetic smoked or vaporised cannabinoids, mainly in “neuropathic” pain, as adjuncts to other drugs including opioids and anticonvulsants. All studies were of short duration (<5 days) and were limited by problems with masking, variability in dosing and strength of THC and lack of functional outcomes. Only 3 of the 6 studies reported a “clinically meaningful pain reduction”, defined as a decrease of 2 points on a 0-to10 numerical pain rating or a 30% improvement in pain intensity. Neurocognitive adverse effects were common but “well tolerated”.

The authors concluded: “Generalizing the use of medical marijuana to all CNCP conditions does not appear to be supported by existing evidence”.

---

9 See footnote 5
10 From this study, Stockings et al (2018) calculated NNTB for 30% pain reduction of 22 and for 50% pain reduction 26. These indices do not support the conclusion of Whiting and colleagues.
Prior to 2015


This paper reviewed 18 trials published between 2003 and 2010, involving 766 patients. Of these trials, 4 were of smoked cannabis in “neuropathic” pain, 7 of oromucosal preparations in mixed pain populations, 4 of nabilone in mixed pain populations, and 2 of dronabinol in mixed pain populations, all placebo-controlled. In 15 trials, a “significant analgesic effect” of the cannabinoid was noted.


These same authors identified another 11 trials published between 2010 and 2014, with 1185 patients. Two trials were of smoked cannabis in “neuropathic” pain, 4 of nabiximols in “neuropathic” pain and 4 of nabilone in mixed pain populations; control groups were variable. In 7 trials there were “significant analgesic effects” of cannabinoids.

The authors concluded overall (8a and 8b): “...there are a total of 22 of 29 RCTs demonstrating that cannabinoids demonstrate a modest analgesic effect and are safe in the management of chronic pain.”


This review identified 18 double-blind randomised controlled trials of sufficient quality that compared any cannabis preparation to placebo among subjects with chronic pain. There was marked variability in study design, methodology and analysis, the last especially with respect to reporting of outcomes. The efficacy analysis (VAS) found a standardised mean difference of -0.61 [95%CI: -0.84 to -0.37] (in favour of cannabinoid). A high risk of harms was found: for alteration of perception OR was 4.5 [95%CI: 3.0 to 6.7] and NNH 7 [6-9]; for altered cognitive function, OR was 4.5 [95%CI: 2.4 to 8.4] and NNH 8 [6-12].

11 Pre-2011 definition
REFERENCES AND BIBLIOGRAPHY (NOT COMPREHENSIVE)


Barnes MP, Barnes JC. Cannabis: The Evidence for Medical Use. Northumberland, Tyne & Wear NHS Foundation Trust, May 2016


Farrell M, Buchbinder R, Hall W. Should doctors prescribe cannabinoids? BMJ 2014; 348:g2737doi: 10.1136/bmj.g2737n (Published 23 April 2014)


Ware MA, Desroches J. Medical Cannabis and Pain. *PAIN* Clinical Updates, 2014, XXII(3).


FACULTY OF PAIN MEDICINE PROFESSIONAL DOCUMENTS

POLICY – defined as ‘a course of action adopted and pursued by the Faculty. These are matters coming within the authority and control of the Faculty.

RECOMMENDATIONS – defined as ‘advisable courses of action’.

GUIDELINES – defined as ‘a document offering advice’. These may be clinical (in which case they will eventually be evidence-based), or non-clinical.

STATEMENTS – defined as ‘a communication setting out information’.

This document has been prepared having regard to general circumstances, and it is the responsibility of the practitioner to have express regard to the particular circumstances of each case, and the application of this policy document in each case.

Professional documents are reviewed from time to time, and it is the responsibility of the practitioner to ensure that the practitioner has obtained the current version. Professional documents have been prepared having regard to the information available at the time of their preparation, and the practitioner should therefore have regard to any information, research or material which may have been published or become available subsequently.

Whilst the College and Faculty endeavours to ensure that documents are as current as possible at the time of their preparation, they take no responsibility for matters arising from changed circumstances or information or material which may have become available subsequently.

Promulgated: 2015
Reviewed: 2018
Date of Current Document: February 11, 2019

© Copyright 2019 – Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists. All rights reserved.

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from ANZCA. Requests and inquiries concerning reproduction and rights should be addressed to the Chief Executive Officer, Australian and New Zealand College of Anaesthetists, 630 St Kilda Road, Melbourne, Victoria 3004, Australia.

FPM Website: http://www.fpm.anzca.edu.au